Analysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Target Price at $93.33

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $93.33.

Several equities research analysts have recently commented on the stock. StockNews.com downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Friday. DA Davidson upped their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Royal Bank of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Canaccord Genuity Group raised their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Finally, Oppenheimer upped their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th.

Insider Transactions at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This represents a 8.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company's stock.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors have recently made changes to their positions in the company. Kestra Investment Management LLC bought a new position in Prestige Consumer Healthcare during the fourth quarter worth about $27,000. Opal Wealth Advisors LLC bought a new stake in shares of Prestige Consumer Healthcare in the 1st quarter worth approximately $38,000. CIBC Private Wealth Group LLC grew its position in Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after acquiring an additional 152 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth about $40,000. Finally, McIlrath & Eck LLC raised its holdings in Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after purchasing an additional 154 shares in the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Down 0.4%

Shares of NYSE:PBH traded down $0.33 during mid-day trading on Thursday, hitting $87.71. The stock had a trading volume of 60,819 shares, compared to its average volume of 296,527. Prestige Consumer Healthcare has a 12-month low of $62.35 and a 12-month high of $90.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The company has a market cap of $4.34 billion, a PE ratio of 20.54, a P/E/G ratio of 2.69 and a beta of 0.44. The company's 50 day moving average is $83.23 and its 200-day moving average is $81.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. The firm had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The firm's revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.02 earnings per share. On average, sell-side analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.